The Authors Reply:  by Bomback, Andrew S. & Markowitz, Glen S.
On ANCA-associated
glomerulonephritis in the very
elderly
To the Editor: I read with interest the article by Bomback
et al.1 regarding outcomes and morbidity in very elderly
patients with pauci-immune vasculitis. A number of additional
limitations were not eluded to in the accompanying editorial:2
18% of the ‘treated’ patients were given a nonstandard of care
regimen of either steroids or mycophenolate mofetil alone,
which would be expected to carry a lower side-effect burden
than deﬁnitive treatment with cyclophosphamide. This may
account for the surprisingly low frequency of infectious
complications in the treated group.
Further, the severity of infectious complications was not
graded, and other common side effects such as anemia were
not reported, along with a lack of functional outcomes such as
time in the hospital.
In making the decision to pursue aggressive treatment
involvement of patients in a shared decision is crucial. It
would be interesting to know whether certain patients had
declined aggressive treatment. There is a lack of clarity
regarding the comorbidities given that no functional data
were recorded such as nursing home residence. Also, certain
comorbidities, such as metastatic malignancy, would have
carried much more weight, and the article does not delineate
the comorbidities in the treated vs. untreated groups.
Other prognostically important information such as
albumin at presentation is absent along with weight, thus
we cannot adjust for peak creatinine levels reﬂecting healthy
patients rather than more severe disease.
Overall, the study provides helpful support for clinicians
initiating immunosuppressive treatment in elderly patients,
but there is a wealth of further information, which needs to be
clariﬁed in the future.
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The Authors Reply: We agree with many of the comments
made by Dr Reschen1 regarding our study on anti-neutrophil
cytoplasmic antibody (ANCA)-associated glomerulonephritis
(GN) in the very elderly.2 As mentioned in our discussion, a
retrospective cohort study such as ours is limited to objective
data that can be drawn from patient charts. In creating our
models to identify parameters at presentation that might
influence outcomes, we focused on histopathological and
clinical variables that were universally collected for all
patients. Patients’ functional and nutritional statuses are
difficult to measure objectively and are inconsistently
recorded, particularly when the diagnosis of pauci-immune
GN is made by a consulting nephrologist meeting the patient
for the first time.
Dr Reschen suggests that infectious complications in this
cohort might be artiﬁcially low, as 18% of treated patients
received steroids or mycophenolate mofetil as induction therapy.
However, as we point out in our discussion, there has been a
shift from oral toward intravenous cyclophosphamide since the
time of this data collection, speciﬁcally to limit cumulative dose
and adverse events.3 Given that almost 60% of the treated
patients in this cohort received at least 6 months of oral
cyclophosphamide, we feel that our reported infectious rate of
38.3% is a reasonable, perhaps even mildly inﬂated, estimate of
infectious risk for very elderly patients who today would most
likely be treated with intravenous cyclophosphamide.
Although we agree with Dr Reschen that functional
outcomes are important, these data were not available.
Instead, we focused on dialysis-free survival in this cohort,
where virtually all patients presented with severe renal failure,
and nearly 70% of patients died or reached end-stage renal
disease within 1 year. Despite the limitations, we feel that this
assembled cohort provides an important source of support for
nephrologists to utilize immunosuppression in very elderly
patients with ANCA-associated disease. The general rules of
treating with immunosuppressive agents—namely, to achieve
the best possible results with the least possible toxicities—still
hold and almost certainly do so with more urgency in this
patient population.
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